43 results about "Pigmented retinal epithelium" patented technology

An apparatus for delivering therapeutic agent to an eye comprises a body, a cannula, a hollow needle, and an actuation assembly. The cannula extends distally from the body and is sized and configured to be insertable between a choroid and a sclera of a patient's eye. The actuation assembly is operable to actuate the needle relative to the cannula to thereby drive a distal portion of the needle along an exit axis that is obliquely oriented relative to the longitudinal axis of the cannula. The cannula may be inserted through a sclerotomy incision to position a distal end of the cannula at a posterior region of the eye, between the choroid and sclera. The needle may be advanced through the choroid to deliver the therapeutic agent adjacent to the potential space between the neurosensory retina and the retinal pigment epithelium layer, adjacent to the area of geographic atrophy.

Intravitreal administration of a JNK-inhibitory peptide less than 150 amino acids in length, containing at least one D-amino acid, and having (a) a JNK-inhibitory sequence of at least any of SEQ ID NO: 1 and SEQ ID NO: 2, and (b) a transport sequence of at least any of SEQ ID NO: 3 and SEQ ID NO: 4 suppressed spermidine-induced retinal pigment epithelial damage, tunicamycin-induced photoreceptor cell damage, and laser-induced choroidal neovascularization. Thus, the JNK-inhibitory peptide of the present invention is useful for prophylaxis or therapy of a retinal disease. By the use of this JNK-inhibitory peptide, a drug and a method are provided which are capable of preventing or treating a retinal disease even by topical administration to the eye, and use of the JKN-inhibitory peptide for manufacturing the drug is also provided.

The invention relates to a nerve stem cell injection made from retina pigment epithelial cell, to treat paralysis agitans, wherein said injection at least comprises 3*106 nerve stem cells of human hRPE, while said nerve stem cells are cultivated from retina pigment epithelial cells. And its production comprises that: (1), separating and cultivating cells, that separating the hRPE cells, mixing uniformly to prepare single cell suspension; (2), hRPE cell cultivation and generation that digests original cultivation liquid, ending digestion, blowing and beating to form cell suspension, eccentrically filtering and removing the upper clear liquid, adding cultivating substrate, to disperse and form cell suspension, filtering with cell screen, transferring cell into cultivating bottle, generating to at least fifth generation; (3), adding common salt into hRPE nerve stem cell, to prepare cell suspension injection.

Provided herein are methods for generating stem cell-derived retinal pigment epithelial monolayer cultures as well as methods of using the same. Also provided are populations of retinal pigment epithelial cells prepared according to these methods. In addition, three-dimensional tissue products derived from human induced pluripotent stem cells are also provided along with methods of making and using the same.

This document provides methods and materials for performing retinal pigment epithelium transplantation. For example, methods and materials for using fibrin supports for retinal pigment epithelium transplantation are provided.

A multi-spot ophthalmic laser device that produces spatially distributed laser spots with the spatial distribution of the laser spots defined by a spot diameter to space ratio in the range 1:2 to 1:20. The multi-spot ophthalmic laser device comprises: a laser module producing a laser pulse or sequence of laser pulses each having: a pulse duration in the range of 10 ps to 20 μs; a wavelength in the range 500 nm to 900 nm; and a pulse energy in the range 10 μJ to 10 mJ per pulse; and an optical beam profiling module that modifies an output beam profile of each pulse of the laser module to deliver multiple spatially distributed laser spots of defined size and energy. The multi-spot ophthalmic laser device is used in a method of improving the function of the retina of a human eye by irradiation through the cornea of the eye to the retinal pigmented epithelium by a treatment laser having a beam profile with spatially distributed energy peaks.

The invention is suitable for the technical field of medical image processing, and provides a fundus hydrops segmentation method of an OCT image, which comprises the following steps of: 1, carrying out noise reduction processing on the input OCT image by using a non-local mean algorithm; 2, correcting the gray level of the OCT image by using an algorithm 1; 3, adopting a Canny edge extraction and second-order polynomial fitting mode to determine the uppermost edge and the lowermost edge as the boundary of the inner boundary membrane and the retinal pigment epithelium, and selecting the region, between the inner boundary membrane and the retinal pigment epithelium, of the image as the region of interest of subsequent processing; 4, clustering by using an improved fuzzy clustering algorithm, and segmenting effusion; and 5, performing level set evolution by using a level set algorithm, and realizing fundus effusion segmentation through iteration. According to the method, pixel data needing to be processed is reduced under the condition that the image quality is guaranteed, the fuzzy clustering result serves as a dynamic constraint item of the level set method to control evolution of the level set, the method is not affected by a randomly-set initial level set, and the accuracy is effectively improved.

A system and process for safely providing retinal phototherapy includes generating first and second light beams of a different wavelength. The first and second light beams are applied to a retinal pigment epithelium (RPE) (24) and choroid (26) of an eye (10). The amount of light reflected from the eye from the first light beam and the second light beam is measured, such as using a reflectometer (110). A level or concentration of the melanin within the eye is calculated using the measured amount of light reflected from the eye from the first and second light beams. When the content or density of melanin in the RPE exceeds a predetermined amount, one or more treatment parameters of the retinal phototherapy is adjusted.